Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details)

v3.19.1
Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Purchase price allocation:    
Goodwill $ 2,189,338 $ 2,189,338
Pelican Therapeutics, Inc. [Member]    
Aggregate consideration:    
Cash consideration 500,000  
Stock consideration 1,052,000  
Contingent consideration 2,385,000  
Total Consideration 3,937,000  
Purchase price allocation:    
Cash acquired 31,199  
In-process R&D 5,866,000  
Goodwill 2,189,338  
Deferred tax liability (2,111,760)  
Net liabilities assumed (1,102,777)  
Fair value of non-controlling interest (935,000)  
Total purchase price $ 3,937,000